These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 19424611)
1. Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors. Shimakage M; Kodama K; Kawahara K; Kim CJ; Ikeda Y; Yutsudo M; Inoue H Oncol Rep; 2009 Jun; 21(6):1367-72. PubMed ID: 19424611 [TBL] [Abstract][Full Text] [Related]
2. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization. Walch AK; Zitzelsberger HF; Aubele MM; Mattis AE; Bauchinger M; Candidus S; Präuer HW; Werner M; Höfler H Am J Pathol; 1998 Oct; 153(4):1089-98. PubMed ID: 9777940 [TBL] [Abstract][Full Text] [Related]
3. Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis. Walter RF; Werner R; Ting S; Vollbrecht C; Theegarten D; Christoph DC; Schmid KW; Wohlschlaeger J; Mairinger FD Oncotarget; 2015 Sep; 6(28):24690-8. PubMed ID: 26008974 [TBL] [Abstract][Full Text] [Related]
4. Expression of drs mRNA in human lung adenocarcinomas. Shimakage M; Takami K; Kodama K; Mano M; Yutsudo M; Inoue H Hum Pathol; 2002 Jun; 33(6):615-9. PubMed ID: 12152160 [TBL] [Abstract][Full Text] [Related]
5. MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma. Lei L; Jiang Z; Zhang G; Cheng Q; Lu H World J Surg Oncol; 2018 Jun; 16(1):110. PubMed ID: 29914531 [TBL] [Abstract][Full Text] [Related]
6. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901). Peng W; Cao L; Chen L; Lin G; Zhu B; Hu X; Lin Y; Zhang S; Jiang M; Wang J; Li J; Li C; Shao L; Du H; Hou T; Chen Z; Xiang J; Pu X; Li J; Xu F; Loong H; Wu L Oncologist; 2022 Mar; 27(2):e116-e125. PubMed ID: 35641209 [TBL] [Abstract][Full Text] [Related]
8. [Expression and clinicopathologic significance of human achaete-scute homolog 1 in pulmonary neuroendocrine tumors]. Li F; Zhong Z; Li R; Huang H; Wang L; Zheng D; Zhang D Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):317-21. PubMed ID: 20677557 [TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects. Neubauer E; Wirtz RM; Kaemmerer D; Athelogou M; Schmidt L; Sänger J; Lupp A Oncotarget; 2016 Jul; 7(27):41959-41973. PubMed ID: 27259241 [TBL] [Abstract][Full Text] [Related]
10. Down-regulation of drs mRNA in human colon adenocarcinomas. Shimakage M; Kawahara K; Kikkawa N; Sasagawa T; Yutsudo M; Inoue H Int J Cancer; 2000 Jul; 87(1):5-11. PubMed ID: 10861446 [TBL] [Abstract][Full Text] [Related]
11. Down-regulation of drs mRNA in human prostate carcinomas. Kim CJ; Shimakage M; Kushima R; Mukaisho K; Shinka T; Okada Y; Inoue H Hum Pathol; 2003 Jul; 34(7):654-7. PubMed ID: 12874760 [TBL] [Abstract][Full Text] [Related]
12. Pulmonary neuroendocrine tumors: study of 90 cases focusing on clinicopathological characteristics, immunophenotype, preoperative biopsy, and frozen section diagnoses. Yeh YC; Chou TY J Surg Oncol; 2014 Mar; 109(3):280-6. PubMed ID: 24301337 [TBL] [Abstract][Full Text] [Related]
13. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Swarts DR; Ramaekers FC; Speel EJ Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738 [TBL] [Abstract][Full Text] [Related]
14. Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors. Asiedu MK; Thomas CF; Dong J; Schulte SC; Khadka P; Sun Z; Kosari F; Jen J; Molina J; Vasmatzis G; Kuang R; Aubry MC; Yang P; Wigle DA Clin Cancer Res; 2018 Apr; 24(7):1691-1704. PubMed ID: 29351916 [No Abstract] [Full Text] [Related]
15. The balance between the expressions of hASH1 and HES1 differs between large cell neuroendocrine carcinoma and small cell carcinoma of the lung. Nasgashio R; Sato Y; Matsumoto T; Kageyama T; Hattori M; Iyoda A; Satoh Y; Ryuge S; Masuda N; Jiang SX; Saegusa M Lung Cancer; 2011 Dec; 74(3):405-10. PubMed ID: 21601304 [TBL] [Abstract][Full Text] [Related]
16. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398 [TBL] [Abstract][Full Text] [Related]
17. Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome. Walter RF; Mairinger FD; Werner R; Vollbrecht C; Hager T; Schmid KW; Wohlschlaeger J; Christoph DC Oncotarget; 2016 Apr; 7(15):20166-79. PubMed ID: 27064343 [TBL] [Abstract][Full Text] [Related]
18. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Travis WD; Rush W; Flieder DB; Falk R; Fleming MV; Gal AA; Koss MN Am J Surg Pathol; 1998 Aug; 22(8):934-44. PubMed ID: 9706973 [TBL] [Abstract][Full Text] [Related]
20. [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?]. Schnabel PA; Junker K Pathologe; 2015 May; 36(3):283-92. PubMed ID: 25956813 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]